Organigram Global Inc. announced that ISS recommends shareholders vote FOR the Transaction Resolution approving the indirect acquisition of Sanity Group GmbH at the March 30, 2026 shareholder meeting, highlighting compelling strategic rationale, BAT's premium financing signaling institutional confidence, credible valuation, and positive market reaction. This endorsement underscores strong support for the €113.4 million upfront deal with potential €113.8 million earn-out.
Key takeaways
ISS report dated March 14, 2026 recommends FOR Transaction Resolution for Sanity Group GmbH acquisition
Upfront consideration €113.4 million (€80.0 million cash + €33.4 million Organigram shares) at deemed C$3.00 per share (71.4% premium)
Contingent earn-out up to €113.8 million based on 12-month post-closing performance
BAT subsidiary completed private placement financing at meaningful premium to market
Shareholder meeting March 30, 2026 at 10:00 a.m. Toronto time
Organigram Board unanimously recommends FOR Transaction Resolution (interested directors abstained)